Evidence map›Paper›PMID 42511710›Full record

ReviewInternational journal of molecular sciences2026

Matvey M Tsyganov, Irina A Tsydenova, Daria S Dolgasheva, Marina K Ibragimova

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Matvey M TsyganovDepartment of Experimental Oncology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 5 Kooperativny Street, 634050 Tomsk, Russia.ORCID 0000-0001-7419-4512
Irina A TsydenovaDepartment of Experimental Oncology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 5 Kooperativny Street, 634050 Tomsk, Russia.ORCID 0000-0002-2716-3075
Daria S DolgashevaDepartment of Experimental Oncology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 5 Kooperativny Street, 634050 Tomsk, Russia.ORCID 0000-0002-6763-920X
Marina K IbragimovaDepartment of Experimental Oncology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 5 Kooperativny Street, 634050 Tomsk, Russia.

Funding

Russian Science Foundation 22-15-00169 (Continuation)
6 · The paper itself

Abstract

DNA double-strand breaks (DSBs), caused by various endogenous and exogenous factors, pose a significant threat to genomic stability. Several conserved repair pathways address DSBs, with homologous recombination (HR) being the only mechanism capable of accurately restoring the original DNA sequence. The

Indexed as

Biomarkers, TumorBRCA1 ProteinGenes, BRCA1Lung NeoplasmsAnimalsHumansBiomarkers, TumorBRCA1 ProteinBRCA1 protein, humanBRCA1BRCA2BRCA-like tumorschemotherapy efficacyhomologous recombination deficiencynon-small cell lung cancersurvival

Identifiers

PMID42511710
PMCPMC13410211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.